Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
BLA Submission Ongoing with U.S. Food and Drug Administration
SAN CARLOS, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news